This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (MOVING)

This study has been terminated.
NeuroCure Clinical Research Center, Charite, Berlin
Information provided by (Responsible Party):
Friedemann Paul, Charite University, Berlin, Germany Identifier:
First received: July 23, 2012
Last updated: August 1, 2017
Last verified: August 2017
In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline.

Condition Intervention Phase
Multiple Sclerosis Drug: Verum arm receiving Gilenya® Drug: Active Comparator receiving Extavia® Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis

Resource links provided by NLM:

Further study details as provided by Friedemann Paul, Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Efficacy parameters
    Decrease of latency of mVEP of the affected eye after 6 months treatment with Gilenya® vs. Extavia® compared to baseline

Secondary Outcome Measures:
  • Efficacy parameters
    Decrease in the latency of the mVEP from the affected eye at the time points 1, 3 and 12 months in comparison to baseline. Retinal nerve fiber layer thickness and macular volume in OCT, visual contrast sensitivity, visual field, Color vision, visual quality of life, in CMRT lesion load in cMRT , neurotrophic factors and axonal damage markers (neurofilament) and neurotrophins (for example, BDNF) in the serum

Enrollment: 8
Study Start Date: July 2013
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fingolimod (Gilenya®)
0,5 mg once a day in the morning, oral
Drug: Verum arm receiving Gilenya®
Active Comparator: Interferon beta-1b (Extavia®)
every second day, s.c.
Drug: Active Comparator receiving Extavia®


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS)
  • ability to consent and a written approval
  • First acute ON attack to the fit eye within 30 days before screening
  • Age 18 - 55 years at screening
  • EDSS ≤ 6.0
  • No MS Attack except for ON in the last 30 days before screening
  • No immunomodulatory therapy for at least three Months (before randomization), or
  • strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months
  • visus in the affected eye at least 0.1
  • latency of Conventional VEP in the affected eye

    • = 115 ms or difference> = 15 ms to the opposite side at a Study at least 4 but no more than 6 weeks after Onset of clinical symptoms
  • At least 2 T2 lesions typical of MS in a previous MRI

Exclusion Criteria:

  • other MS course than RRMS
  • any condition which could interfere or prevent the MRI study or other investigations
  • known allergy or intolerance, or other contraindication against Gd-DTPA
  • Patients with known contraindications to treatment with fingolimod (Gilenya ®) or interferon beta-1b Extavia ®
  • Competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01647880

Charité-Universitätsmedizin Berlin
Berlin, Germany
Sankt Josefs Krankenhaus Potsdam Neurologie
Potsdam, Germany
Sponsors and Collaborators
Charite University, Berlin, Germany
NeuroCure Clinical Research Center, Charite, Berlin
Study Director: Olaf Hoffmann, PD Dr. med. Charite- NeuroCure
  More Information

Responsible Party: Friedemann Paul, Sponsor Deputy, Charite University, Berlin, Germany Identifier: NCT01647880     History of Changes
Other Study ID Numbers: MOVING
Study First Received: July 23, 2012
Last Updated: August 1, 2017

Additional relevant MeSH terms:
Multiple Sclerosis
Optic Neuritis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Fingolimod Hydrochloride
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Adjuvants, Immunologic processed this record on August 22, 2017